This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Nov. 8, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and pharmacists through their clinical experience with patients, today announced that it will be attending the 117
th Annual Meeting of the American Academy of Ophthalmology (AAO) in
November 16-19 (Booth #5058). Imprimis' presence at this conference is primarily to continue the pre-launch assessments of two of its proprietary ophthalmic sterile injectable compounded formulations, which Imprimis expects to make available to the ophthalmology community in 2014.
Imprimis will also be hosting two events, during which they will be soliciting feedback from the ophthalmology community regarding the utility and commercialization potential of its proprietary ophthalmic compounded formulations.
To schedule meetings with Imprimis or to attend an Imprimis sponsored event, please contact
Forest Flodin, Director of Corporate Development, at
ABOUT IMPRIMIS PHARMACEUTICALS:
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company focused on the commercial development of novel drug formulations and proprietary drug delivery vehicles. Imprimis believes in the power of the clinical interaction of one patient, one physician and one pharmacist to build novel therapeutic approaches that have broad market appeal. Drug formulations created by pharmacists and physicians for a specific patient's use are investigated using through a proprietary and rigorous evaluation process, the Asset Review Methodology (ARM™), in order to assess potential for commercialization. Following this evaluation process, including clinical development, the company may choose to pursue FDA approval through the FDA's Section 505(b)(2) development pathway, or selectively make its treatment options available to the market through pharmacy compounding. In addition, Imprimis expects to seek partnerships with wholesalers in order to make its drug delivery technologies available to compounding pharmacies across
North America. The company's current focus is in the Ophthalmology, Wound Management, Urology and Pain therapeutic areas.